Table 3.

Multivariate Cox regression analysis of overall survival in subgroups

	Deaths/patients	Hazard ratio (95% CI)	P		Deaths/patients	Hazard ratio (95% CI)	P
Age (years) <60				Lung cancer
Standard‐dose RT	407/447	1		Standard‐dose RT	428/443	1
Dose‐escalated RT	305/340	0.832 (0.712–0.972)	0.021	Dose‐escalated RT	158/164	0.894 (0.740–1.079)	0.241
Age (years) ≥60				Non‐lung cancer
Standard‐dose RT	654/678	1		Standard‐dose RT	633/682	1
Dose‐escalated RT	302/330	0.844 (0.731–0.976)	0.022	Dose‐escalated RT	449/506	0.785 (0.691–0.891)	<0.00
Female				ECOG 0–1
Standard‐dose RT	624/650	1		Standard‐dose RT	473/515	1
Dose‐escalated RT	341/370	0.834 (0.726–0.958)	0.012	Dose‐escalated RT	322/354	0.817 (0.705–0.948)	0.008
Male				ECOG 2–4
Standard‐dose RT	437/475	1		Standard‐dose RT	588/610	1
Dose‐escalated RT	266/300	0.867 (0.737–0.989)	0.037	Dose‐escalated RT	285/316	0.851 (0.731–0.991)	0.038
Absence of symptoms				Time to metastases >1 year
Standard‐dose RT	70/72	1		Standard‐dose RT	265/283	1
Dose‐escalated RT	51/61	0.581 (0.402–0.840)	0.004	Dose‐escalated RT	220/252	0.734(0.610–0.885)	<0.00
Pain				Time to metastases ≤1 year)
Standard‐dose RT	692/735	1		Standard‐dose RT	796/842	1
Dose‐escalated RT	423/469	0.836 (0.736–0.950)	0.006	Dose‐escalated RT	387/418	0.880 (0.775–0.990)	0.049
Neurological deficits				Metastases to 1 site
Standard‐dose RT	299/318	1		Standard‐dose RT	220/270	1
Dose‐escalated RT	133/141	0.918 (0.733–1.15)	0.457	Dose‐escalated RT	120/168	0.844 (0.750–0.949)	0.005
Spinal metastases				Metastases to >1 site
Standard‐dose RT	813/863	1		Standard‐dose RT	841/855	1
Dose‐escalated RT	340/368	0.800 (0.668–0.955)	0.015	Dose‐escalated RT	487/502	0.805 (0.635–1.020)	0.073
Non‐spinal metastases
Standard‐dose RT	248/262	1
Dose‐escalated RT	267/302	0.859 (0.754–0.978)	0.022

RT, radiotherapy; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group.